Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. acta pharmacologica sinica 
3. review 
4. article
Show authors
•  Review
•  Published: 05 June 2013


Mesenchymal stem cells: a new
trend for cell therapy
•  Xin Wei1,
•  Xue Yang2,
•  Zhi-peng Han3,
•  Fang-fang Qu3,
•  Li Shao
1 &
•  …
•  Yu-fang Shi
2 
Acta Pharmacologica Sinica volume 34, pages 747–754 (2013)Cite
this article
•  83k Accesses
•  850 Citations
•  49 Altmetric
•  Metrics details
Abstract
Mesenchymal stem cells (MSCs), the major stem cells for cell
therapy, have been used in the clinic for approximately 10 years.
From animal models to clinical trials, MSCs have afforded promise
in the treatment of numerous diseases, mainly tissue injury and
immune disorders. In this review, we summarize the recent
opinions on methods, timing and cell sources for MSC
administration in clinical applications, and provide an overview of
mechanisms that are significant in MSC-mediated therapies.
Although MSCs for cell therapy have been shown to be safe and
effective, there are still challenges that need to be tackled before
their wide application in the clinic.


Similar content being viewed by others
[image]
The secretion profile of mesenchymal stem cells and
potential applications in treating human diseases
Article Open access 21 March 2022
[image]
Mesenchymal stem cell-derived extracellular vesicles
for immunomodulation and regeneration: a next
generation therapeutic tool?
Article Open access 04 July 2022
[image]
Mesenchymal stem cells in treating human diseases:
molecular mechanisms and clinical studies
Article Open access 22 August 2025
Log in or create a free account to read this
content
Gain free access to this article, as well as selected content from this
journal and more on nature.com
 Access through your institution
or
 Sign in or create an account 
[image] Continue with Google 
[image] Continue with ORCiD 


References
1. Bianchi G, Borgonovo G, Pistoia V, Raffaghello L .
Immunosuppressive cells and tumour microenvironment:
focus on mesenchymal stem cells and myeloid derived
suppressor cells. Histol Histopathol 2011; 26: 941–51.
CAS  PubMed  Google Scholar 
2. Prockop DJ . Marrow stromal cells as stem cells for
nonhematopoietic tissues. Science 1997; 276: 71–4.
CAS  PubMed  Google Scholar 
3. Granero-Molto F, Weis JA, Longobardi L, Spagnoli A . Role of
mesenchymal stem cells in regenerative medicine: application
to bone and cartilage repair. Expert Opin Biol Ther 2008; 8:
255–68.
CAS  PubMed  Google Scholar 
4. Salem HK, Thiemermann C . Mesenchymal stromal cells:
current understanding and clinical status. Stem Cells 2010; 28:
585–96.
CAS  PubMed  Google Scholar 
5. Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M,
Takeda S, et al. Bone marrow stromal cells generate muscle
cells and repair muscle degeneration. Science 2005; 309: 314–
7.
CAS  PubMed  Google Scholar 
6. Bianco P, Robey PG, Simmons PJ . Mesenchymal stem cells:
revisiting history, concepts, and assays. Cell Stem Cell 2008; 2:
313–9.
CAS  PubMed  PubMed Central  Google Scholar 
7. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R,


Mosca JD, et al. Multilineage potential of adult human
mesenchymal stem cells. Science 1999; 284: 143–7.
CAS  PubMed  Google Scholar 
8. Anjos-Afonso F, Bonnet D . Nonhematopoietic/endothelial
SSEA-1+ cells define the most primitive progenitors in the
adult murine bone marrow mesenchymal compartment. Blood
2007; 109: 1298–306.
CAS  PubMed  Google Scholar 
9. In't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de
Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of
mesenchymal stem cells of fetal or maternal origin from
human placenta. Stem Cells 2004; 22: 1338–45.
Google Scholar 
10. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et
al. Multilineage cells from human adipose tissue: implications
for cell-based therapies. Tissue Eng 2001; 7: 211–28.
CAS  PubMed  Google Scholar 
11. Tzaribachev N, Vaegler M, Schaefer J, Reize P, Rudert M,
Handgretinger R, et al. Mesenchymal stromal cells: a novel
treatment option for steroid-induced avascular osteonecrosis.
Isr Med Assoc J 2008; 10: 232–4.
PubMed  Google Scholar 
12. Richardson SM, Hoyland JA . Stem cell regeneration of
degenerated intervertebral discs: current status. Curr Pain
Headache Rep 2008; 12: 83–8.
PubMed  Google Scholar 
13. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS,
Cattaneo S, et al. Cardiac repair with intramyocardial
injection of allogeneic mesenchymal stem cells after
myocardial infarction. Proc Natl Acad Sci U S A 2005; 102:


11474–9.
CAS  PubMed  PubMed Central  Google Scholar 
14. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA . Allogeneic
human mesenchymal stem cells for treatment of E. coli
endotoxin-induced acute lung injury in the ex vivo perfused
human lung. Proc Natl Acad Sci U S A 2009; 106: 16357–62.
CAS  PubMed  PubMed Central  Google Scholar 
15. Parekkadan B, van Poll D, Suganuma K, Carter EA,
Berthiaume F, Tilles AW, et al. Mesenchymal stem cell-
derived molecules reverse fulminant hepatic failure. PLoS One
2007; 2: e941.
PubMed  PubMed Central  Google Scholar 
16. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C .
Administered mesenchymal stem cells protect against
ischemic acute renal failure through differentiation-
independent mechanisms. Am J Physiol Renal Physiol 2005;
289: F31–42.
PubMed  Google Scholar 
17. Kim JM, Lee ST, Chu K, Jung KH, Song EC, Kim SJ, et al.
Systemic transplantation of human adipose stem cells
attenuated cerebral inflammation and degeneration in a
hemorrhagic stroke model. Brain Res 2007; 1183: 43–50.
CAS  PubMed  Google Scholar 
18. Inoue Y, Iriyama A, Ueno S, Takahashi H, Kondo M, Tamaki
Y, et al. Subretinal transplantation of bone marrow
mesenchymal stem cells delays retinal degeneration in the
RCS rat model of retinal degeneration. Exp Eye Res 2007; 85:
234–41.
CAS  PubMed  Google Scholar 
19. Chen L, Tredget EE, Wu PY, Wu Y . Paracrine factors of


mesenchymal stem cells recruit macrophages and endothelial
lineage cells and enhance wound healing. PLoS One 2008; 3:
e1886.
PubMed  PubMed Central  Google Scholar 
20. Hayashi Y, Tsuji S, Tsujii M, Nishida T, Ishii S, Iijima H, et al.
Topical implantation of mesenchymal stem cells has
beneficial effects on healing of experimental colitis in rats. J
Pharmacol Exp Ther 2008; 326: 523–31.
CAS  PubMed  Google Scholar 
21. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I,
Gerdoni E, et al. Mesenchymal stem cells ameliorate
experimental autoimmune encephalomyelitis inducing T-cell
anergy. Blood 2005; 106: 1755–61.
CAS  PubMed  Google Scholar 
22. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon
PL, Neel M, et al. Transplantability and therapeutic effects of
bone marrow-derived mesenchymal cells in children with
osteogenesis imperfecta. Nat Med 1999; 5: 309–13.
CAS  PubMed  Google Scholar 
23. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro
C, Rodriguez-Montes JA . A phase I clinical trial of the
treatment of Crohn's fistula by adipose mesenchymal stem
cell transplantation. Dis Colon Rectum 2005; 48: 1416–23.
PubMed  Google Scholar 
24. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan
M, Uzunel M, et al. Treatment of severe acute graft-versus-
host disease with third party haploidentical mesenchymal
stem cells. Lancet 2004; 363: 1439–41.
PubMed  Google Scholar 
25. Noth U, Steinert AF, Tuan RS . Technology insight: adult


mesenchymal stem cells for osteoarthritis therapy. Nat Clin
Pract Rheumatol 2008; 4: 371–80.
PubMed  Google Scholar 
26. Erokhin VV, Vasil'eva IA, Konopliannikov AG, Chukanov VI,
Tsyb AF, Bagdasarian TR, et al. Systemic transplantation of
autologous mesenchymal stem cells of the bone marrow in
the treatment of patients with multidrug-resistant pulmonary
tuberculosis. Probl Tuberk Bolezn Legk 2008; (10): 3–6.
Google Scholar 
27. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, et al. Autologous
bone marrow mesenchymal stem cell transplantation in liver
failure patients caused by hepatitis B: short-term and long-
term outcomes. Hepatology 2011; 54: 820–8.
PubMed  Google Scholar 
28. Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F,
Aghajani K, Jafari F, et al. Improvement of liver function in
liver cirrhosis patients after autologous mesenchymal stem
cell injection: a phase I–II clinical trial. Eur J Gastroenterol
Hepatol 2009; 21: 1199–205.
CAS  PubMed  Google Scholar 
29. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, et al.
Comparison of bone marrow mesenchymal stem cells with
bone marrow-derived mononuclear cells for treatment of
diabetic critical limb ischemia and foot ulcer: a double-blind,
randomized, controlled trial. Diabetes Res Clin Pract 2011; 92:
26–36.
PubMed  Google Scholar 
30. Yamada Y, Ueda M, Hibi H, Baba S . A novel approach to
periodontal tissue regeneration with mesenchymal stem cells
and platelet-rich plasma using tissue engineering technology:
a clinical case report. Int J Periodontics Restorative Dent 2006;
26: 363–9.


PubMed  Google Scholar 
31. Rasulov MF, Vasilchenkov AV, Onishchenko NA,
Krasheninnikov ME, Kravchenko VI, Gorshenin TL, et al. First
experience of the use bone marrow mesenchymal stem cells
for the treatment of a patient with deep skin burns. Bull Exp
Biol Med 2005; 139: 141–4.
CAS  PubMed  Google Scholar 
32. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et
al. Intravenous hMSCs improve myocardial infarction in mice
because cells embolized in lung are activated to secrete the
anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54–
63.
Article  CAS  PubMed  PubMed Central  Google Scholar 
33. Roddy GW, Oh JY, Lee RH, Bartosh TJ, Ylostalo J, Coble K, et
al. Action at a distance: systemically administered adult stem/
progenitor cells (MSCs) reduce inflammatory damage to the
cornea without engraftment and primarily by secretion of
TSG-6. Stem Cells 2011; 29: 1572–9.
CAS  PubMed  Google Scholar 
34. Zeng X, Zeng YS, Ma YH, Lu LY, Du BL, Zhang W, et al. Bone
marrow mesenchymal stem cells in a three dimensional
gelatin sponge scaffold attenuate inflammation, promote
angiogenesis and reduce cavity formation in experimental
spinal cord injury. Cell Transplant 2011; 20: 1881–99.
PubMed  Google Scholar 
35. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et
al. Interleukin 1 receptor antagonist mediates the
antiinflammatory and antifibrotic effect of mesenchymal stem
cells during lung injury. Proc Natl Acad Sci U S A 2007; 104:
11002–7.
CAS  PubMed  PubMed Central  Google Scholar 


36. Goodwin M, Sueblinvong V, Eisenhauer P, Ziats NP, LeClair L,
Poynter ME, et al. Bone marrow-derived mesenchymal
stromal cells inhibit Th2–mediated allergic airways
inflammation in mice. Stem Cells 2011; 29: 1137–48.
CAS  PubMed  PubMed Central  Google Scholar 
37. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG,
Frick J, et al. Mesenchymal stem cells home to injured tissues
when co-infused with hematopoietic cells to treat a radiation-
induced multi-organ failure syndrome. J Gene Med 2003; 5:
1028–38.
PubMed  Google Scholar 
38. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P,
Neunhoeffer F, et al. Application of multipotent mesenchymal
stromal cells in pediatric patients following allogeneic stem
cell transplantation. Blood Cells Mol Dis 2008; 40: 25–32.
PubMed  Google Scholar 
39. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D,
Broadwater G, et al. Efficacy and safety of ex vivo cultured
adult human mesenchymal stem cells (Prochymal) in
pediatric patients with severe refractory acute graft-versus-
host disease in a compassionate use study. Biol Blood Marrow
Transplant 2011; 17: 534–41.
CAS  PubMed  Google Scholar 
40. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk
J, et al. Adult human mesenchymal stem cells added to
corticosteroid therapy for the treatment of acute graft-versus-
host disease. Biol Blood Marrow Transplant 2009; 15: 804–11.
CAS  PubMed  Google Scholar 
41. Wu KH, Chan CK, Tsai C, Chang YH, Sieber M, Chiu TH, et al.
Effective treatment of severe steroid-resistant acute graft-
versus-host disease with umbilical cord-derived mesenchymal
stem cells. Transplantation 2011; 91: 1412–6.


PubMed  Google Scholar 
42. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I,
et al. Mesenchymal stem cells for treatment of steroid-
resistant, severe, acute graft-versus-host disease: a phase II
study. Lancet 2008; 371: 1579–86.
CAS  PubMed  Google Scholar 
43. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, et al.
Umbilical cord mesenchymal stem cell transplantation in
severe and refractory systemic lupus erythematosus. Arthritis
Rheum 2010; 62: 2467–75.
CAS  PubMed  Google Scholar 
44. Carrion F, Nova E, Ruiz C, Diaz F, Inostroza C, Rojo D, et al.
Autologous mesenchymal stem cell treatment increased T
regulatory cells with no effect on disease activity in two
systemic lupus erythematosus patients. Lupus 2010; 19: 317–
22.
CAS  PubMed  Google Scholar 
45. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R,
Avanzini MA, Ubezio C, et al. Autologous bone marrow-
derived mesenchymal stromal cells in the treatment of
fistulising Crohn's disease. Gut 2011; 60: 788–98.
PubMed  Google Scholar 
46. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich
BB, Verspaget HW, et al. Autologous bone marrow-derived
mesenchymal stromal cell treatment for refractory luminal
Crohn's disease: results of a phase I study. Gut 2010; 59:
1662–9.
PubMed  Google Scholar 
47. Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K .
Autologous mesenchymal stem cell therapy delays the
progression of neurological deficits in patients with multiple


system atrophy. Clin Pharmacol Ther 2008; 83: 723–30.
CAS  PubMed  Google Scholar 
48. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-
Kurkalli B, Gomori JM, Kassis I, et al. Safety and
immunological effects of mesenchymal stem cell
transplantation in patients with multiple sclerosis and
amyotrophic lateral sclerosis. Arch Neurol 2010; 67: 1187–94.
PubMed  PubMed Central  Google Scholar 
49. Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He
XL, et al. The mesenchymal stem cells in multiple sclerosis
(MSCIMS) trial protocol and baseline cohort characteristics:
an open-label pre-test: post-test study with blinded outcome
assessments. Trials 2011; 12: 62.
PubMed  PubMed Central  Google Scholar 
50. Choi MR, Kim HY, Park JY, Lee TY, Baik CS, Chai YG, et al.
Selection of optimal passage of bone marrow-derived
mesenchymal stem cells for stem cell therapy in patients with
amyotrophic lateral sclerosis. Neurosci Lett 2010; 472: 94–8.
CAS  PubMed  Google Scholar 
51. Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S,
Onodera R, et al. Intravenous administration of auto serum-
expanded autologous mesenchymal stem cells in stroke. Brain
2011; 134: 1790–807.
PubMed  PubMed Central  Google Scholar 
52. Mannon PJ . Remestemcel-L: human mesenchymal stem cells
as an emerging therapy for Crohn's disease. Expert Opin Biol
Ther 2011; 11: 1249–56.
PubMed  Google Scholar 
53. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley
AM, Deans R, et al. Human mesenchymal stem cells engraft


and demonstrate site-specific differentiation after in utero
transplantation in sheep. Nat Med 2000; 6: 1282–6.
CAS  PubMed  Google Scholar 
54. Lama VN, Smith L, Badri L, Flint A, Andrei AC, Murray S, et
al. Evidence for tissue–resident mesenchymal stem cells in
human adult lung from studies of transplanted allografts. J
Clin Invest 2007; 117: 989–96.
CAS  PubMed  PubMed Central  Google Scholar 
55. Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T,
Nishina H, et al. Transplantation of bone marrow cells
reduces CCl4-induced liver fibrosis in mice. Hepatology 2004;
40: 1304–11.
PubMed  Google Scholar 
56. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic
benefit of intravenous administration of bone marrow stromal
cells after cerebral ischemia in rats. Stroke 2001; 32: 1005–
11.
CAS  PubMed  Google Scholar 
57. Mohamadnejad M, Namiri M, Bagheri M, Hashemi SM,
Ghanaati H, Zare Mehrjardi N, et al. Phase 1 human trial of
autologous bone marrow-hematopoietic stem cell
transplantation in patients with decompensated cirrhosis.
World J Gastroenterol 2007; 13: 3359–63.
CAS  PubMed  PubMed Central  Google Scholar 
58. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F,
Levacher B, et al. Bone marrow mesenchymal stem cells
suppress lymphocyte proliferation in vitro but fail to prevent
graft-versus-host disease in mice. J Immunol 2006; 176: 7761–
7.
CAS  PubMed  Google Scholar 


59. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al.
Mesenchymal stem cell-mediated immunosuppression occurs
via concerted action of chemokines and nitric oxide. Cell Stem
Cell 2008; 2: 141–50.
CAS  PubMed  Google Scholar 
60. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, et al. Mesenchymal
stem cells: a new strategy for immunosuppression and tissue
repair. Cell Res 2010; 20: 510–8.
CAS  PubMed  Google Scholar 
61. Chen L, Tredget EE, Liu C, Wu Y . Analysis of allogenicity of
mesenchymal stem cells in engraftment and wound healing in
mice. PLoS One 2009; 4: e7119.
PubMed  PubMed Central  Google Scholar 
62. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M,
Mossafa H, et al. Clinical-grade production of human
mesenchymal stromal cells: occurrence of aneuploidy without
transformation. Blood 2010; 115: 1549–53.
CAS  PubMed  Google Scholar 
63. Bocelli-Tyndall C, Zajac P, Di Maggio N, Trella E, Benvenuto
F, Iezzi G, et al. Fibroblast growth factor 2 and platelet-
derived growth factor, but not platelet lysate, induce
proliferation-dependent, functional class II major
histocompatibility complex antigen in human mesenchymal
stem cells. Arthritis Rheum 2010; 62: 3815–25.
CAS  PubMed  Google Scholar 
64. Karp JM, Leng Teo GS . Mesenchymal stem cell homing: the
devil is in the details. Cell Stem Cell 2009; 4: 206–16.
CAS  PubMed  Google Scholar 
65. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall
RY, et al. Isolated allogeneic bone marrow-derived


mesenchymal cells engraft and stimulate growth in children
with osteogenesis imperfecta: Implications for cell therapy of
bone. Proc Natl Acad Sci U S A 2002; 99: 8932–7.
CAS  PubMed  PubMed Central  Google Scholar 
66. Mahmood A, Lu D, Lu M, Chopp M . Treatment of traumatic
brain injury in adult rats with intravenous administration of
human bone marrow stromal cells. Neurosurgery 2003; 53:
697–702.
PubMed  Google Scholar 
67. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S,
Tessone A, et al. Systemic delivery of bone marrow-derived
mesenchymal stem cells to the infarcted myocardium:
feasibility, cell migration, and body distribution. Circulation
2003; 108: 863–8.
PubMed  Google Scholar 
68. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et
al. Intravenous hMSCs improve myocardial infarction in mice
because cells embolized in lung are activated to secrete the
anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54–
63.
CAS  PubMed  PubMed Central  Google Scholar 
69. Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA,
Wraith JE, et al. A small proportion of mesenchymal stem
cells strongly expresses functionally active CXCR4 receptor
capable of promoting migration to bone marrow. Blood 2004;
104: 2643–5.
CAS  PubMed  Google Scholar 
70. Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T .
Efficient homing of multipotent adult mesenchymal stem cells
depends on FROUNT-mediated clustering of CCR2. Cell Stem
Cell 2008; 2: 566–75.


CAS  PubMed  Google Scholar 
71. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, et al. Targeted
migration of mesenchymal stem cells modified with CXCR4
gene to infarcted myocardium improves cardiac performance.
Mol Ther 2008; 16: 571–9.
CAS  PubMed  Google Scholar 
72. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E,
et al. Mesenchymal stem cells display coordinated rolling and
adhesion behavior on endothelial cells. Blood 2006; 108:
3938–44.
PubMed  Google Scholar 
73. Ko IK, Kim BG, Awadallah A, Mikulan J, Lin P, Letterio JJ, et
al. Targeting improves MSC treatment of inflammatory bowel
disease. Mol Ther 2010; 18: 1365–72.
CAS  PubMed  PubMed Central  Google Scholar 
74. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P .
MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive
capacity of human mesenchymal stem cells: differential
regulation by inflammatory cytokines. Blood 2007; 109:
4055–63.
CAS  PubMed  Google Scholar 
75. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ .
Mesenchymal stem cells prevent the rejection of fully
allogenic islet grafts by the immunosuppressive activity of
matrix metalloproteinase-2 and -9. Diabetes 2009; 58: 1797–
806.
CAS  PubMed  PubMed Central  Google Scholar 
76. Shi M, Li J, Liao L, Chen B, Li B, Chen L, et al. Regulation of
CXCR4 expression in human mesenchymal stem cells by
cytokine treatment: role in homing efficiency in NOD/SCID
mice. Haematologica 2007; 92: 897–904.


PubMed  Google Scholar 
77. Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, et al.
Inflammatory cytokine-induced intercellular adhesion
molecule-1 and vascular cell adhesion molecule-1 in
mesenchymal stem cells are critical for immunosuppression. J
Immunol 2010; 184: 2321–8.
CAS  PubMed  Google Scholar 
78. Dvorak HF . Tumors: wounds that do not heal. Similarities
between tumor stroma generation and wound healing. N Engl
J Med 1986; 315: 1650–9.
CAS  PubMed  Google Scholar 
79. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F .
Inflammation and tumor microenvironments: defining the
migratory itinerary of mesenchymal stem cells. Gene Ther
2008; 15: 730–8.
CAS  PubMed  Google Scholar 
80. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ,
Andreeff M . Bone marrow-derived mesenchymal stem cells as
vehicles for interferon-beta delivery into tumors. Cancer Res
2002; 62: 3603–8.
CAS  PubMed  Google Scholar 
81. Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, et
al. Cancer gene therapy using mesenchymal stem cells
expressing interferon-beta in a mouse prostate cancer lung
metastasis model. Gene Ther 2008; 15: 1446–53.
CAS  PubMed  PubMed Central  Google Scholar 
82. Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, et al. The
effects of mesenchymal stem cells injected via different routes
on modified IL-12-mediated antitumor activity. Gene Ther
2011; 18: 488–95.


CAS  PubMed  PubMed Central  Google Scholar 
83. Loebinger MR, Eddaoudi A, Davies D, Janes SM .
Mesenchymal stem cell delivery of TRAIL can eliminate
metastatic cancer. Cancer Res 2009; 69: 4134–42.
CAS  PubMed  PubMed Central  Google Scholar 
84. Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan
S . Therapeutic potential of mesenchymal stem cells
producing interferon-alpha in a mouse melanoma lung
metastasis model. Stem Cells 2008; 26: 2332–8.
CAS  PubMed  PubMed Central  Google Scholar 
85. Roger M, Clavreul A, Venier-Julienne MC, Passirani C, Sindji
L, Schiller P, et al. Mesenchymal stem cells as cellular vehicles
for delivery of nanoparticles to brain tumors. Biomaterials
2010; 31: 8393–401.
CAS  PubMed  Google Scholar 
86. Cheng H, Kastrup CJ, Ramanathan R, Siegwart DJ, Ma M,
Bogatyrev SR, et al. Nanoparticulate cellular patches for cell-
mediated tumoritropic delivery. ACS Nano 2010; 4: 625–31.
CAS  PubMed  PubMed Central  Google Scholar 
87. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall
RY, et al. Isolated allogeneic bone marrow-derived
mesenchymal cells engraft and stimulate growth in children
with osteogenesis imperfecta: Implications for cell therapy of
bone. Proc Natl Acad Sci U S A 2002; 99: 8932–7.
CAS  PubMed  PubMed Central  Google Scholar 
88. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake
H, et al. Nonhematopoietic mesenchymal stem cells can be
mobilized and differentiate into cardiomyocytes after
myocardial infarction. Blood 2004; 104: 3581–7.
CAS  PubMed  Google Scholar 


89. Dennis JE, Konstantakos EK, Arm D, Caplan AI . In vivo
osteogenesis assay: a rapid method for quantitative analysis.
Biomaterials 1998; 19: 1323–8.
CAS  PubMed  Google Scholar 
90. Ohgushi H, Kotobuki N, Funaoka H, Machida H, Hirose M,
Tanaka Y, et al. Tissue engineered ceramic artificial joint —
ex vivo osteogenic differentiation of patient mesenchymal
cells on total ankle joints for treatment of osteoarthritis.
Biomaterials 2005; 26: 4654–61.
CAS  PubMed  Google Scholar 
91. Kon E, Muraglia A, Corsi A, Bianco P, Marcacci M, Martin I, et
al. Autologous bone marrow stromal cells loaded onto porous
hydroxyapatite ceramic accelerate bone repair in critical-size
defects of sheep long bones. J Biomed Mater Res 2000; 49:
328–37.
CAS  PubMed  Google Scholar 
92. Solchaga LA, Temenoff JS, Gao J, Mikos AG, Caplan AI,
Goldberg VM . Repair of osteochondral defects with
hyaluronan- and polyester-based scaffolds. Osteoarthritis
Cartilage 2005; 13: 297–309.
PubMed  Google Scholar 
93. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T,
Meldrum DR . Human mesenchymal stem cells stimulated by
TNF-alpha, LPS, or hypoxia produce growth factors by an NF
kappa B- but not JNK-dependent mechanism. Am J Physiol
Cell Physiol 2008; 294: C675–82.
CAS  PubMed  Google Scholar 
94. Caplan AI, Dennis JE . Mesenchymal stem cells as trophic
mediators. J Cell Biochem 2006; 98: 1076–84.
CAS  PubMed  Google Scholar 


95. Jing Y, Han Z, Zhang S, Liu Y, Wei L . Epithelial-
mesenchymal transition in tumor microenvironment. Cell
Biosci 2011; 1: 29.
CAS  PubMed  PubMed Central  Google Scholar 
96. Xu G, Zhang Y, Zhang L, Ren G, Shi Y . The role of IL-6 in
inhibition of lymphocyte apoptosis by mesenchymal stem
cells. Biochem Biophys Res Commun 2007; 361: 745–50.
CAS  PubMed  PubMed Central  Google Scholar 
97. Liu Y, Han ZP, Zhang SS, Jing YY, Bu XX, Wang CY, et al.
Effects of inflammatory factors on mesenchymal stem cells
and their role in the promotion of tumor angiogenesis in
colon cancer. J Biol Chem 2011; 286: 25007–15.
CAS  PubMed  PubMed Central  Google Scholar 
98. Cao W, Yang Y, Wang Z, Liu A, Fang L, Wu F, et al. Leukemia
inhibitory factor inhibits T helper 17 cell differentiation and
confers treatment effects of neural progenitor cell therapy in
autoimmune disease. Immunity 2011; 35: 273–84.
CAS  PubMed  Google Scholar 
99. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, et
al. Pre-treatment of mesenchymal stem cells with a
combination of growth factors enhances gap junction
formation, cytoprotective effect on cardiomyocytes, and
therapeutic efficacy for myocardial infarction. J Am Coll
Cardiol 2008; 51: 933–43.
CAS  PubMed  Google Scholar 
100. Schnabel LV, Lynch ME, van der Meulen MC, Yeager AE,
Kornatowski MA, Nixon AJ . Mesenchymal stem cells and
insulin-like growth factor-I gene-enhanced mesenchymal stem
cells improve structural aspects of healing in equine flexor
digitorum superficialis tendons. J Orthop Res 2009; 27: 1392–
8.


CAS  PubMed  Google Scholar 
101. Uccelli A, Moretta L, Pistoia V . Mesenchymal stem cells in
health and disease. Nat Rev Immunol 2008; 8: 726–36.
CAS  PubMed  Google Scholar 
102. Han Z, Jing Y, Zhang S, Liu Y, Shi Y, Wei L . The role of
immunosuppression of mesenchymal stem cells in tissue
repair and tumor growth. Cell Biosci 2012; 2: 8.
CAS  PubMed  PubMed Central  Google Scholar 
103. Kanichai M, Ferguson D, Prendergast PJ, Campbell VA .
Hypoxia promotes chondrogenesis in rat mesenchymal stem
cells: a role for AKT and hypoxia-inducible factor
(HIF)-1alpha. J Cell Physiol 2008; 216: 708–15.
CAS  PubMed  Google Scholar 
104. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini
A, et al. Role for interferon-gamma in the immunomodulatory
activity of human bone marrow mesenchymal stem cells. Stem
Cells 2006; 24: 386–98.
CAS  PubMed  Google Scholar 
105. Aggarwal S, Pittenger MF . Human mesenchymal stem cells
modulate allogeneic immune cell responses. Blood 2005; 105:
1815–22.
CAS  PubMed  Google Scholar 
106. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M,
Williams P, Birman E, et al. Mesenchymal stromal cells
ameliorate experimental autoimmune encephalomyelitis by
inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-
dependent manner. J Immunol 2009; 182: 5994–6002.
CAS  PubMed  Google Scholar 
107. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F,


Cancedda R, et al. Bone marrow mesenchymal progenitor
cells inhibit lymphocyte proliferation by activation of the
programmed death 1 pathway. Eur J Immunol 2005; 35:
1482–90.
CAS  PubMed  Google Scholar 
108. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee
A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via
prostaglandin E2-dependent reprogramming of host
macrophages to increase their interleukin-10 production. Nat
Med 2009; 15: 42–9.
CAS  PubMed  Google Scholar 
Download references
Acknowledgements
This project was supported by the Key Basic Research Project of
China (Grant No 2011CB966200, 2010CB945600, and
2011CB965100); Key Project of the National Natural Science
Foundation of China (Grant No 81030041); the National Natural
Science Foundation of China (Grant No 31171321 and 81101622);
Special Funds for the National Key Sci-Tech Special Project of China
(Grant No 2012ZX10002-016 and 2012ZX10002011-011); the
Shanghai Science and Technology Committee (Grant No
11ZR1449500 and 12ZR1439800); and the Science Fund for
Creative Research Groups, NSFC, China (Grant No 81221061).
Author information
Authors and Affiliations
1. Renji Hospital, Shanghai Jiao Tong University School of
Medicine, Shanghai, 200127, China
Xin Wei & Li Shao


2. Key Laboratory of Stem Cell Biology, Institute of Health
Sciences, Shanghai Jiao Tong University School of Medicine,
Shanghai, 200025, China
Xue Yang & Yu-fang Shi
3. Tumor Immunology and Gene Therapy Center, Eastern
Hepatobiliary Surgery Hospital, the Second Military Medical
University, Shanghai, 200433, China
Zhi-peng Han & Fang-fang Qu
Authors
1. Xin Wei
View author publications
Search author on:PubMed Google Scholar
2. Xue Yang
View author publications
Search author on:PubMed Google Scholar
3. Zhi-peng Han
View author publications
Search author on:PubMed Google Scholar
4. Fang-fang Qu
View author publications
Search author on:PubMed Google Scholar
5. Li Shao
View author publications
Search author on:PubMed Google Scholar
6. Yu-fang Shi
View author publications
Search author on:PubMed Google Scholar


Corresponding authors
Correspondence to Li Shao or Yu-fang Shi.
PowerPoint slides
PowerPoint slide for Fig. 1
PowerPoint slide for Fig. 2
PowerPoint slide for Fig. 3
Rights and permissions
Reprints and permissions
About this article
Cite this article
Wei, X., Yang, X., Han, Zp. et al. Mesenchymal stem cells: a new
trend for cell therapy. Acta Pharmacol Sin 34, 747–754 (2013).
https://doi.org/10.1038/aps.2013.50
Download citation
•  Received: 11 March 2013
•  Accepted: 05 April 2013
•  Published: 05 June 2013
•  Issue date: June 2013
•  DOI: https://doi.org/10.1038/aps.2013.50


Share this article
Anyone you share the following link with will be able to read this
content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative
Keywords
•  mesenchymal stem cell
•  cell therapy
•  tissue injury
•  degenerative disease
•  immune disorder
•  graft-versus-host disease
•  immunomodulation
•  trophic factor
This article is cited by
•  Umbilical cord-derived mesenchymal stem cell
sheets transplanted subcutaneously enhance cell
retention and survival more than dissociated
stem cell injections
○  Mitsuyoshi Nakao
○  Makoto Matsui
○  Kenichi Nagase
Stem Cell Research & Therapy (2023)


•  Mesenchymal stem cells in the treatment of
osteogenesis imperfecta
○  Erica Lang
○  Julie A. Semon
Cell Regeneration (2023)
•  Mesenchymal stem cell-derived secretomes-
enriched alginate/ extracellular matrix hydrogel
patch accelerates skin wound healing
○  Jae Won Kwon
○  Cininta Savitri
○  Kwideok Park
Biomaterials Research (2023)
•  Systematic comparison of nonviral gene delivery
strategies for efficient co-expression of two
transgenes in human mesenchymal stem cells
○  Tyler Kozisek
○  Luke Samuelson
○  Angela K. Pannier
Journal of Biological Engineering (2023)
•  Nongenetic surface engineering of mesenchymal
stromal cells with polyvalent antibodies to
enhance targeting efficiency
○  Tenghui Ye
○  Xi Liu
○  Peng Shi
Nature Communications (2023)


Advertisement
[image]
Explore content
•  Research articles
•  Reviews & Analysis
•  News & Comment
•  Current issue
•  Collections
•  Subscribe
•  Sign up for alerts
•  RSS feed
About the journal
•  Aims & Scope
•  Journal Information
•  About the Editors
•  Editorial Board
•  About the Partner
•  Contact
•  For Advertisers
•  Subscribe
•  Open Access Fees and Funding
Publish with us
•  For Authors & Referees
•  Language editing services
•  Open access funding


•  Submit manuscript
Search
Search articles by subject, keyword or author
Show results from All journals This journal
Search
Advanced search
Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors
•  Editorial policies
Acta Pharmacologica Sinica (Acta Pharmacol Sin)
ISSN 1745-7254 (online)
ISSN 1671-4083 (print)
nature.com sitemap
About Nature Portfolio
•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io
•  Nature Index


Publishing policies
•  Nature portfolio policies
•  Open access
Author & Researcher services
•  Reprints & permissions
•  Research data
•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions
Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content
Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa
•  Nature China
•  Nature India


•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies
•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights
[image]
© 2025 Springer Nature Limited


[image]


